CA2342040A1 - Anaerobic bacterium as a drug for cancer gene therapy - Google Patents

Anaerobic bacterium as a drug for cancer gene therapy Download PDF

Info

Publication number
CA2342040A1
CA2342040A1 CA002342040A CA2342040A CA2342040A1 CA 2342040 A1 CA2342040 A1 CA 2342040A1 CA 002342040 A CA002342040 A CA 002342040A CA 2342040 A CA2342040 A CA 2342040A CA 2342040 A1 CA2342040 A1 CA 2342040A1
Authority
CA
Canada
Prior art keywords
bacterium
dna
protein
antitumor substance
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002342040A
Other languages
French (fr)
Other versions
CA2342040C (en
Inventor
Minoru Fujimori
Shun'ichiro Taniguchi
Jun Amano
Kazuyuki Yazawa
Yasunobu Kano
Toshiyuki Nakamura
Takayuki Sasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azusapharma Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2342040A1 publication Critical patent/CA2342040A1/en
Application granted granted Critical
Publication of CA2342040C publication Critical patent/CA2342040C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Abstract

The present invention provides a bacterium belonging to the genus Bifidobacterium, by which DNA coding for a protein having an antitumor activity or DNA coding for a protein having the activity of converting a precursor of an antitumor substance into the antitumor substance is delivered to tumor tissues specifically under anaerobic conditions thereby expressing the protein encoded by the DNA, as well as a pharmaceutical composition comprising said anaerobic bacterium.

Claims (27)

1. A method for delivering a gene in a system for delivering DNA specifically to tumor tissues under anaerobic conditions, wherein a bacterium belonging to the genus Bifidobacterjum is used as a gene delivery vector and then the DNA delivered specifically to tumor tissues under anaerobic conditions is expressed in said tumor tissues.
2. A method for delivering a gene in a system for delivering DNA specifically to tumor tissues under anaerobic conditions, wherein a bacterium belonging to the genus Bifidobacterium and having the DNA coding for a protein which has a higher activity than in its parent strain is used as a gene delivery vector and then the DNA delivered specifically to tumor tissues under anaerobic conditions is expressed in said tumor tissues.
3. A method for delivering a gene in a system for delivering DNA specifically to tumor tissues under anaerobic conditions, wherein a bacterium belonging to the genus Bifidobacterium transformed with a recombinant DNA having said DNA is used as a gene delivery vector and the DNA delivered specifically to tumor tissues under anaerobic conditions is expressed in the tumor tissues.
4. The method as claimed in any one of Claims 1 to 3, wherein the DNA is selected from the group consisting of:
(a) DNA coding for a protein having an antitumor activity, and (b) DNA coding for a protein having an activity of converting a precursor of an antitumor substance into the antitumor substance.
5. The method as claimed in Claim 4, wherein the protein having an antitumor activity is interleukin-2.
6. The method as claimed in Claim 4, wherein the precursor of an antitumor substance is selected from the group consisting of 5-fluorocytosine, 5-aziridino-2,4-dinitrobenzamide, ganciclovir, a glucuronic acid-conjugated antitumor substance and a lysine-conjugated antitumor substance.
7. The method as claimed in Claim 4 , wherein the protein having the activity of converting a precursor of an antitumor substance into the antitumor substance is a protein selected from the group consisting of cytosine deaminase, nitroreductase, herpes simplex virus type 1 thymidine kinase and .beta.-glucuronidase.
8. The method as claimed in Claim 3, wherein the recombinant DNA is an expression vector.
9. The method as claimed in Claim 8, wherein the expression vector has a promoter and a terminator functioning in a bacterium belonging to the genus Bifidobacterium.
10. The method as claimed in Claim 9, wherein the promoter and terminator are those involved in expressing a gene coding for histone-like DNA-binding protein(HU protein) derived from Bjfidobacterjum longum.
11. The method as claimed in Claim 9, wherein the promoter and terminator are DNAs located at the 1- to 192-positions and at the 472- to 600-positions respectively in the nucleotide sequence set forth in SEQ ID NO: 1.
12. The method as claimed in any one of Claims 1 to 11, wherein the bacterium is Bifidobacterium longum.
13. The method as claimed in any one of Claims 1 to 4 or 6 to 12, wherein the bacterium is Bifidobacterium longum 105-A/pBLES100-S-eCD (FERM BP-7274).
14. A method for expressing a gene coding for a protein having an antitumor activity in tissue tumors specifically, which comprises use of the bacterium as claimed in any one of Claims 1 to 5 or 8 to 12.
15. A method for expressing a gene coding for a protein having the activity of converting a precursor of an antitumor substance into the antitumor substance in tissue tumors specifically, which comprises use of the bacterium as claimed in any one of Claims 1 to 4 or 6 to 12.
16. A pharmaceutical composition comprising the bacterium as claimed in any one of Claims 1 to 13.
17. The pharmaceutical composition as claimed in Claim 16, wherein the pharmaceutical composition comprises a combination of the bacterium as claimed in any one of Claims 1 to 4 or 6 to 13 and the precursor of an antitumor substance.
18. The pharmaceutical composition as claimed in Claim 16, wherein the pharmaceutical composition comprises the bacterium as claimed, in any one of Claims 1 to 4 or 6 to 13 and the precursor of an antitumor substance.
19. The pharmaceutical composition as claimed in any one of Claims 16 to 18, wherein the bacterium is Bifidobacterium longum.
20. The pharmaceutical composition as claimed in any one of Claims 16 to 19, wherein bacterium is Bifidobacterium longum 105-A/pBLES100-S-eCD (FERM BP-7274).
21. A bacterium belonging to the genus Bifidobacterium, which is used in the method as claimed in any one of Claims 1 to 13.
22. Bifidobacterium longum 105-A/pBLES100-S-eCD (FERM
BP-7274.
23. DNA having the nucleotide sequence set forth in SEQ
ID NO: 1.
24. A method of treating a solid tumor, which comprises use of the method as claimed in any one of Claims 1 to 15.
25. A method of treating a solid tumor, which comprises administering the bacterium as claimed in any one of Claims 1 to 4 or 6 to 13 in combination with the precursor of an antitumor substance.
26. An anaerobic bacterium belonging to the genus Bifidobacterium capable of expressing a gene coding for a protein having an antitumor activity in only cancer cells under substantially anaerobic conditions.
27. An anaerobic bacterium belonging to the genus Bifidobacterium capable of expressing a gene coding for a protein having the activity of converting a precursor of an antitumor substance with low toxicity to humans and animals into an antitumor substance in only cancer cells under substantially anaerobic conditions.
CA2342040A 2000-09-21 2001-03-26 Anaerobic bacterium as a drug for cancer gene therapy Expired - Lifetime CA2342040C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP287688/2000 2000-09-21
JP2000287688 2000-09-21

Publications (2)

Publication Number Publication Date
CA2342040A1 true CA2342040A1 (en) 2002-03-21
CA2342040C CA2342040C (en) 2012-07-10

Family

ID=18771403

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2342040A Expired - Lifetime CA2342040C (en) 2000-09-21 2001-03-26 Anaerobic bacterium as a drug for cancer gene therapy

Country Status (2)

Country Link
US (2) US20020054865A1 (en)
CA (1) CA2342040C (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
ATE420160T1 (en) 2003-06-18 2009-01-15 Genelux Corp MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF
US20070270504A1 (en) * 2003-06-20 2007-11-22 Avalon Pharmaceuticals, Inc. Identification of Therapeutic Agents Using Genetic Fingerprinting
DE602005025946D1 (en) 2004-11-24 2011-02-24 Anaeropharma Science Inc New shuttle vector
US8734779B2 (en) * 2005-04-08 2014-05-27 Anaeropharma Science Inc. 5-fluorouracil-resistant bacteria and method for production thereof
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2242516A1 (en) * 2008-01-11 2010-10-27 Genelux Corporation Methods and compositions for detection of bacteria and treatment of diseases and disorders
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
ES2628378T3 (en) * 2008-04-17 2017-08-02 Anaeropharma Science, Inc. Plasmid vector
ES2569659T3 (en) 2009-09-17 2016-05-12 Morishita Jintan Co., Ltd. Gene expressing a fusion protein presented on the surface of bifidobacterium
CA2787787A1 (en) * 2010-01-29 2011-08-04 Anaeropharma Science, Inc. Transformation plasmid
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016088376A1 (en) * 2014-12-03 2016-06-09 株式会社アネロファーマ・サイエンス Coexpression plasmid
CN107208108B (en) 2015-01-19 2019-05-17 国立大学法人信州大学 Therapeutic agent for ischemic diseases
US10076556B2 (en) 2015-01-29 2018-09-18 Oxyrase, Inc. Methods for inhibiting tumor growth
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4486407A (en) * 1983-02-28 1984-12-04 Fumiaki Taguchi Method for enhancing production of interferon
JPH05174434A (en) * 1991-12-26 1993-07-13 Sharp Corp Magneto-optical recording disk
US6984513B2 (en) * 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6416754B1 (en) * 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
IT1270123B (en) 1994-10-05 1997-04-28 Dompe Spa PHARMACEUTICAL COMPOSITIONS CONTAINING ENGINEERED MICROORGANISMS AND THEIR USE FOR THERAPY
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
FR2746016B1 (en) * 1996-03-15 1998-04-17 COMBINATIONS OF ENZYMES FOR THE DESTRUCTION OF PROLIFERATIVE CELLS
JPH10111517A (en) 1996-10-08 1998-04-28 Omron Corp Liquid crystal display device
CN1253551C (en) * 1997-09-10 2006-04-26 维昂药品公司 Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
ID29150A (en) * 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
WO2001014579A2 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules

Also Published As

Publication number Publication date
CA2342040C (en) 2012-07-10
US7740835B2 (en) 2010-06-22
US20020054865A1 (en) 2002-05-09
US20050025745A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
CA2342040A1 (en) Anaerobic bacterium as a drug for cancer gene therapy
EP3353298B1 (en) Allele selective gene editing and uses thereof
US11274302B2 (en) Specific synthetic chimeric Xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency
Theys et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum
Caruso et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.
EP2682459B1 (en) Oncolytic adenovirus for target therapy of human tumor and use thereof
AU752146B2 (en) Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
Mohyeldin et al. Gene and viral therapy for glioblastoma: a review of clinical trials and future directions
Kirn Series Introduction: Replication-selective microbiological agents: fighting cancer with targeted germ warfare
AU3041701A (en) Therapeutic uses of lna-modified oligonucleotides
NZ255950A (en) Recombinant adenoviruses expressing cytokines, antitumour treatment
EP2274422B1 (en) Expression vector
WO2000046355B1 (en) Telomerase reverse transcriptase transcriptional regulatory sequences
JP2001519148A5 (en)
WO2019139229A1 (en) Microorganism for delivering drug for treatment of gastrointestinal disease, which expresses and secretes p8 protein, and pharmaceutical composition for preventing or treating gastrointestinal disease, which includes the same
KR20070107671A (en) Novel shuttle vector
ES2320157T3 (en) PARTS KIT DESIGNED TO PUT INTO PRACTICE AN ATTITUMORAL OR ANTIVIRICAL TREATMENT IN A MAMMER.
CA2294709A1 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
CN106520778A (en) Modified interleukin 12 and purpose of modified interleukin 12 in preparation of medicine for treating tumour
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
CN109641020A (en) There is the hsv vector of enhancing duplication in cancer cell
EP4352226A1 (en) Peptide nucleic acids for spatiotemporal control of crispr-cas binding
JPWO2020109339A5 (en)
GB9923423D0 (en) Promoting gene expression
GB2362884A (en) Extended duration of airway gene therapy

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210326